IMMUNOTHERAPY

This early-phase study will test whether spending time in a cool room can make standard immunotherapy work better for people with solid tumors. Twenty-four adults will receive their usual PD-1/PD-L1 inhibitor treatment while also being exposed to mild cold (around 18°C) for 12 ho…

This study tests whether adding a probiotic called Lactobacillus johnsonii to standard chemotherapy and immunotherapy can help control advanced lung, breast, or stomach cancers. About 156 adults with these cancers will be randomly assigned to receive either the probiotic or a pla…

This study tests whether adding a special type of radiation (quad shot radiotherapy) to a drug called QL1706 (which boosts the immune system) plus standard chemotherapy can better control advanced non-small cell lung cancer. About 104 people with stage IV lung cancer that has not…

This study tests two different drug combinations given before surgery for people with a specific genetic type of stomach or gastroesophageal junction cancer (dMMR/MSI-H). The goal is to see if these treatments can completely eliminate the tumor before it is removed. About 30 adul…

This pilot study looks at whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard sur…

This study is for people with advanced biliary tract cancer whose disease is stable after initial chemotherapy and immunotherapy. It tests whether adding different drugs (lenvatinib, venadaparib, or IL-2) to maintenance immunotherapy can keep the cancer under control longer. Abou…

This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) can shrink or eliminate tumors in women with a specific type of endometrial cancer (mismatch repair-deficient). The goal is to see if these drugs can be an alternative to surgery. Abo…

This study tests two drug combinations given before surgery for people with locally advanced colon cancer that is pMMR (a common type). One group gets immunotherapy (iparomlimab/tuvonralimab) plus chemotherapy (CAPEOX). The other group gets the same plus propranolol, a beta-block…

This study tests whether giving a short, high-dose course of radiation along with immunotherapy before surgery is safe and effective for people with retroperitoneal sarcoma, a rare cancer in the abdomen. About 28 adults whose tumors are hard to remove completely will receive this…

This study tests whether giving the immunotherapy drug pembrolizumab before planned surgery can make some colon cancers disappear completely. About 152 adults with a specific genetic type of colon cancer (dMMR) will receive different doses of the drug. If scans and scopes show no…

This study tests whether adding a targeted chemoembolization procedure (TACE) to standard immunotherapy can improve outcomes for people with advanced liver cancer that cannot be removed by surgery. About 90 participants will receive both treatments to see if the combination shrin…

This study tests whether giving an immunotherapy drug (atezolizumab) before surgery can help the immune system fight liver cancer more effectively. About 30 adults with early-stage liver cancer will receive the drug before their tumor is removed. The goal is to see if this approa…

This study looks at whether a 12-week exercise program can improve how well immunotherapy works in people with non-small cell lung cancer. One hundred participants will either do moderate or high-intensity interval cycling, or receive standard exercise advice. Researchers will me…

This study is testing a new blood test that measures how active your immune cells are. The goal is to see if this test can predict whether immunotherapy will work for people with advanced solid tumors. About 100 adults starting standard immunotherapy will participate. The test me…

This study looks at a specific type of stomach cancer (dMMR/MSI-H) that often responds well to immunotherapy, but about half of patients do not. Researchers want to understand why some patients benefit and others don't, by studying tumor samples before and during treatment. The g…

This study tests if a small, wearable patch called TempTraq can catch fevers early in cancer patients getting immunotherapy. Fevers can be a sign of cytokine release syndrome (CRS), a serious side effect. The patch monitors temperature continuously, which may help doctors act fas…

This study tests whether using a Fitbit and weekly symptom surveys can help doctors remotely monitor people with advanced melanoma who are starting immunotherapy. About 40 participants will be randomly assigned to use the digital monitoring tool or standard care. The goal is to s…